Abstract
Protein–protein interactions (PPIs) represent an extremely attractive class of potential new targets for therapeutic intervention; however, the shallow extended character of many PPIs can render developing inhibitors against them as exceptionally difficult. Yet this problem can be made tractable by taking advantage of the fact that large interacting surfaces are often characterized by confined “hot spot” regions, where interactions contribute disproportionately to overall binding energies. Peptides afford valuable starting points for developing PPI inhibitors because of their high degrees of functional diversity and conformational adaptability. Unfortunately, contacts afforded by the 20 natural amino acids may be suboptimal and inefficient for accessing both canonical binding interactions and transient “cryptic” binding pockets. Oxime ligation represents a class of biocompatible “click” chemistry that allows the structural diversity of libraries of aldehydes to be rapidly evaluated within the context of a parent oxime-containing peptide platform. Importantly, oxime ligation represents a form of post solid-phase diversification, which provides a facile and empirical means of identifying unanticipated protein–peptide interactions that may substantially increase binding affinities and selectivity. The current review will focus on the authors’ use of peptide ligation to optimize PPI antagonists directed against several targets, including tumor susceptibility gene 101 (Tsg101), protein tyrosine phosphatases (PTPases) and the polo-like kinase 1 (Plk1). This should provide insights that can be broadly directed against an almost unlimited range of physiologically important PPIs.
Highlights
There are estimated to be more than 400,000 protein–protein interactions (PPIs) comprising the human “interactome” and collectively, these represent an extremely attractive class of potential new targets for therapeutic intervention against a broad range of diseases, including several cancers [1,2,3].The shallow, extended character of many PPIs can render developing inhibitors against them as exceptionally challenging
Hot spots tend to occur packed in clusters, where they form interaction networks that can act in cooperative fashion to promote overall PPI stability [7]
There are a number of challenges that must be addressed in using peptides to develop PPI inhibitors
Summary
There are estimated to be more than 400,000 protein–protein interactions (PPIs) comprising the human “interactome” and collectively, these represent an extremely attractive class of potential new targets for therapeutic intervention against a broad range of diseases, including several cancers [1,2,3]. The high degrees of conformational flexibility exhibited by peptides makes the application of Molecules 2020, 25, 2807 secondary conformational constraint a potentially important consideration [11,12,13]. Peptides afford high degrees of functional diversity, contacts afforded by the 20 natural constraint a potentially important consideration [11,12,13]. Peptides afford high amino acids may be suboptimal and inefficient for accessing both canonical binding interactions and degrees functional diversity, contacts transientof“cryptic”. Chemistry can be abyrapid and easy way introduce structural diversity [14] It may be it may be limited its requirement for to product purification prior to biological evaluation. 1 (Plk1).tyrosine phosphatases (PTPases) and the polo-like kinase 1 (Plk1)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
